Αρχική World News CD19-Directed CAR T-Cell Therapy Leads to Exceptionally Long Remissions in Some Patients... World News CD19-Directed CAR T-Cell Therapy Leads to Exceptionally Long Remissions in Some Patients with Relapsed or Refractory B-Cell non-Hodgkin Lymphomas Από Ogkologos - 16 Ιουλίου, 2026 275 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from 10-year follow-up of a phase II study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR FDA Approves Capmatinib for Metastatic NSCLC 29 Αυγούστου, 2022 NGS Is Effective in Identifying Actionable Genetic Alterations for Investigational Targeted... 13 Απριλίου, 2022 How a Musician Copes With Life With Metastatic Breast Cancer 17 Μαρτίου, 2021 Rescued From Complete Darkness 1 Ιουλίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Teen Invents ‘Resilience Bra’ To Help Breast Cancer Patients With Post-Mastectomy... EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab FDA Approves Bosutinib for Paediatric Patients with Chronic Myelogenous Leukaemia Regional Node Radiotherapy Significantly Reduced Breast Cancer Mortality and All-Cause Mortality...